BioPorto

Pre-Annual General Meeting Information • Mar 22, 2015

Today, BioPorto has received notice that BioPorto's Board of Directors has
received shareholder proxies to vote at BioPorto’s Annual General Meeting on
April 10, 2015. BioPorto's Board of Directors will hereinafter control 9,5% of
the shares and voting rights in BioPorto A/S.

After the Annual General Meeting the proxies will expire and BioPorto's Board
of Directorswill thereafter control under 5% of the shares and voting rights in
BioPorto A/S.

For further information, please contact:

Gry Husby Larsen, Legal Counsel

Telephone +45 4529 0000, e-mail investor@bioporto.com

The kidney biomarker NGAL

Every year about 13 million people are struck by acute kidney injury worldwide,
of whom about 4 million die. Nevertheless, there has been no real progress in
methods of diagnosing kidney injury over the last half century. Existing
methods, such as serum creatinine determination, only signal kidney failure
24-72 hours after the injury has taken place. In contrast, NGAL rises to
diagnostic levels within a few hours of kidney injury and thus enables the
physician to make vital clinical decisions before the damage progresses to
potentially fatal renal shutdown. In addition to helping the patient,
cost-benefit analyses show that implementing NGAL testing will contribute to
reducing hospital costs in the management of kidney injury and its
consequences.

About BioPorto

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides
healthcare professionals in clinical and research settings a range of
diagnostic tests and antibodies. Our pioneering product portfolio includes
assays for underserved disease states such as NGAL for acute kidney injury. We
sell our products in more than 80 countries through diverse sales channels and
partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on
the NASDAQ Copenhagen stock exchange.